• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Evidence-based Practice
      Center for Medical Technology Assessment
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [20537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) Assessment of hip protectors for users at risk of falls
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection tools for emotional distress in adult people with cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023     NIHR Health Technology Assessment programme Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: cryotherapy for the prevention of taxane-induced peripheral neuropathy]
2023     Agency for Care Effectiveness (ACE) Echinocandins for treating invasive candidiasis
2023     Agency for Care Effectiveness (ACE) Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023     Agency for Care Effectiveness (ACE) Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023     Agency for Care Effectiveness (ACE) Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: continuum of care and services for individuals with a traumatic spinal cord injury in Québec - characteristics, care pathways and clinical outcomes for adults from 2014 to 2020]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: characteristics and needs of targeted rehabilitation clienteles for young people with adjustment problems aged 10 or older]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next-generation sequencing (NGS) panels for intellectual disability and global developmental delay - Assessment report on the repatriation of a test performed outside Québec]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn – prophylaxis in children and adolescents with hemophilia B]
2023     Health Information and Quality Authority (HIQA) A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023     Health Information and Quality Authority (HIQA) Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: barriers and facilitators encountered by women living with a physical disability (PD), intellectual disability (ID) or autism spectrum disorder (ASD) when using perinatal services]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Addendum to Commission A22-71]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiate diagnostic measures in the presence of symptoms and signs suggestive of urinary tract infection (cystitis and pyelonephritis) and initiate first-line pharmacological treatment for cystitis in an individual 14 years of age and older]
2023     Belgian Health Care Knowledge Centre (KCE) Evaluation of digital medical technologies
2023     Center for Evidence-based Practice (CEP) Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023     Scottish Health Technologies Group (SHTG) Bacteriophage therapy for patients with difficult to treat bacterial infections
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: wound care-assessment, management, and optimal treatment use]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: effectiveness of rehabilitation models and approaches for young people with adjustment problems]
2023     Health Information and Quality Authority (HIQA) Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023     Norwegian Institute of Public Health (NIPH) [Triclosan coated sutures for prevention of surgical site infection - Protocol for health technology assessment - project description]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Update: Functioning and disability - An evidence map]
2023     Norwegian Institute of Public Health (NIPH) Health technology assessment of 177Lu- PSMA-617 treatment for metastatic castration resistant prostate cancer - Protocol for Health technology assessment - project description
2023     Ontario Health Supplemental breast screening for people with dense breasts
2023     Ontario Health Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023     Ontario Health Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023     Ontario Health Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023     Ontario Health Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Effects of treatment and social support measures in comorbidity]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Home abortion]
2023     Norwegian Institute of Public Health (NIPH) [Surgery for degenerative rotator cuff tears: a health technology assessment]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchoscopy: use in lung nodules placement markers and resection process. Horizon Scanning Technologies]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic navigation bronchocopy with or without assisted robotics: use in lung nodules diagnosing process. Horizon Scanning Technologies]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for advanced or metastatic urothelial carcinoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for patients with clear-cell renal-cell carcinoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in non-small-cell lung cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for melanoma treatment in adults]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Phakic intraocular lenses for high-grade myopia]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for head and neck cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasound therapy for scar tissue]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Intensity-modulated radiotherapy for prostate cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy in selected orthopedic conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Cryopreservation of eggs and sperm in patients initiating cancer therapy that may affect fertility]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Trastuzumab with pertuzumab in HER2-positive breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Platelet-rich plasma in certain orthopedic conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin in keratoconus]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fluorodopa PET scanning in Parkinson’s disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Vagus nerve stimulation for drug-resistant epilepsy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]